A New Jersey-based pharmaceutical company has agreed to pay $25 million for allegedly engaging in a price-fixing scheme for a generic cholesterol drug.
“Illegal collaboration on the price or supply of drugs increases costs both to federal health care programs and beneficiaries,” said the Department of Justice’s (DOJ) Principal Deputy Assistant Attorney General Brian Boynton. “The department will use every tool at its disposal to prevent such conduct and to protect these taxpayer-funded programs from abuse.”
The DOJ alleged that between 2013 and 2015, Glenmark Pharmaceuticals Inc., in Mahwah, New Jersey, violated the federal Anti-Kickback Statute.
This statute prohibits companies from making or receiving payments in exchange for the purchase or sale of drugs funded by federal health care plans.
The statute was written to prevent “improper financial incentives” from compromising health care costs, the DOJ said. […]
— Read More: www.theepochtimes.com
-
Learn the TRUTH about Gold IRAs and how most precious metals companies play dirty.
